Document Detail

Laser photodynamic therapy for bladder cancer.
MedLine Citation:
PMID:  2945058     Owner:  NLM     Status:  MEDLINE    
The lack of a tumor-localization aid for transitional cell carcinoma of the bladder and the known cytotoxic effect of light-activated intracellular hematoporphyrin derivative (HpD) prompted the initiation of a trial of HpD photodynamic therapy in patients with focal and diffuse bladder cancer. An argon-ion, pumped-dye laser was used as a source of red light. In 15 patients with focal disease and circumscribed treatment, 3-month follow-up cystoscopic examination showed disappearance of the lesions, but the subsequent recurrence rate seemed high. Therefore, whole-bladder HpD photodynamic therapy was administered to 14 patients with diffuse resistant carcinoma in situ. Three of these patients had focal recurrent disease. The only adverse effects of therapy were cutaneous photosensitivity and bladder irritability. HpD seems to be a good tumor-localizing aid for transitional cell carcinoma of the bladder, and HpD photodynamic therapy effectively destroys this type of carcinoma.
R C Benson
Related Documents :
18826578 - Low grade papillary transitional cell carcinoma pelvic recurrence masquerading as high ...
7571218 - Bladder-sparing multimodality treatment of muscle-invasive bladder cancer: a five-year ...
25186488 - Therapy-related chronic myelogenous leukemia following rfm therapy in a patient with fo...
3215248 - Prognosis of bladder cancer. iii. the value of radical cystectomy in the management of ...
24344018 - Clinical and prognostic importance of xiap and usp8 in advanced stages of non-small cel...
8078728 - Bone metastases in wilms' tumor--report of three cases and review of literature.
Publication Detail:
Type:  Journal Article    
Journal Detail:
Title:  Mayo Clinic proceedings     Volume:  61     ISSN:  0025-6196     ISO Abbreviation:  Mayo Clin. Proc.     Publication Date:  1986 Nov 
Date Detail:
Created Date:  1986-11-20     Completed Date:  1986-11-20     Revised Date:  2013-12-13    
Medline Journal Info:
Nlm Unique ID:  0405543     Medline TA:  Mayo Clin Proc     Country:  UNITED STATES    
Other Details:
Languages:  eng     Pagination:  859-64     Citation Subset:  AIM; IM    
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Antineoplastic Agents / therapeutic use*
Carcinoma in Situ / drug therapy
Carcinoma, Transitional Cell / drug therapy*
Fiber Optic Technology
Hematoporphyrin Derivative
Hematoporphyrins / therapeutic use*
Neoplasm Recurrence, Local
Photochemotherapy / instrumentation,  methods*
Physical Phenomena
Urinary Bladder Neoplasms / drug therapy*
Reg. No./Substance:
0/Antineoplastic Agents; 0/Hematoporphyrins; 67XQY1V3KH/Argon; 68335-15-9/Hematoporphyrin Derivative

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  Differentiation of myeloid leukemic cells in vitro demonstrated by microcalorimetry: stimulation of ...
Next Document:  Percutaneous transluminal coronary angioplasty: current status and future trends.